Literature DB >> 31825011

Extent of Exclusions for Chronic Conditions in Breast Cancer Trials.

Ian M Kronish1, Kathleen Fenn1, Laura Cohen1, Dawn L Hershman1, Paige Green2, Sung A Jenny Lee1, Jerry Suls2.   

Abstract

Experts have expressed concerns that patients with chronic conditions are being excessively excluded from cancer randomized clinical trials (RCTs), limiting generalizability. Accordingly, we queried clinicaltrials.gov to determine the extent to which patients with chronic conditions were excluded from phase III cancer trials, using National Cancer Institute-sponsored breast cancer RCTs as a test case. Two physicians independently coded for the presence of 19 prevalent chronic conditions within eligibility criteria. They also coded for exclusions based on performance status and vague criteria that could have broadly excluded patients with chronic conditions. The search identified 58 RCTs, initiated from 1993 to 2012. Overall, 88% of trials had at least one exclusion for a chronic condition, performance status, or vague criterion. The three most commonly excluded conditions were chronic kidney disease, heart failure, and ischemic heart disease. Our study demonstrated that patients with prevalent chronic conditions were commonly excluded from National Cancer Institute-sponsored RCTs. Published by Oxford University Press 2018.

Entities:  

Year:  2018        PMID: 31825011      PMCID: PMC6649727          DOI: 10.1093/jncics/pky059

Source DB:  PubMed          Journal:  JNCI Cancer Spectr        ISSN: 2515-5091


  2 in total

1.  Ribociclib plus letrozole in subgroups of special clinical interest with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: Subgroup analysis of the phase IIIb CompLEEment-1 trial.

Authors:  Paul Cottu; Alistair Ring; Hikmat Abdel-Razeq; Paolo Marchetti; Fatima Cardoso; Javier Salvador Bofill; Miguel Martín; Lakshmi Menon-Singh; Jiwen Wu; Michelino De Laurentiis
Journal:  Breast       Date:  2022-01-31       Impact factor: 4.254

Review 2.  Cardiovascular Safety Assessment in Cancer Drug Development.

Authors:  Ohad Oren; Tomas G Neilan; Michael G Fradley; Deepak L Bhatt
Journal:  J Am Heart Assoc       Date:  2021-12-16       Impact factor: 6.106

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.